Antibody-Drug Conjugates for Cancer Treatment

The concept of exploiting the specific binding properties of monoclonal antibodies as a mechanism for selective delivery of cytotoxic agents to tumor cells is an attractive solution to the challenge of increasing the therapeutic index of cell-killing agents for treating cancer. All three parts of an...

Full description

Saved in:
Bibliographic Details
Published in:Annual review of medicine 2018-01, Vol.69 (1), p.191-207
Main Authors: Lambert, John M, Berkenblit, Anna
Format: Article
Language:English
Subjects:
ADC
Anaplastic large-cell lymphoma
antibody-drug conjugate
Antigens
Breast cancer
Cancer therapies
Cell surface
Cells
Chemical compounds
Clinical trials
Cytotoxic agents
cytotoxic payload
Cytotoxicity
ErbB-2 protein
Hodgkin's lymphoma
Lymphoma
Metastases
Monoclonal antibodies
monoclonal antibody
Solid tumors
Targeted cancer therapy
targeted drug delivery
Trastuzumab
Tumor cells
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The concept of exploiting the specific binding properties of monoclonal antibodies as a mechanism for selective delivery of cytotoxic agents to tumor cells is an attractive solution to the challenge of increasing the therapeutic index of cell-killing agents for treating cancer. All three parts of an antibody-drug conjugate (ADC)-the antibody, the cytotoxic payload, and the linker chemistry that joins them together-as well as the biologic properties of the cell-surface target antigen are important in designing an effective anticancer agent. The approval of brentuximab vedotin in 2011 for treating relapsed Hodgkin's lymphoma and systemic anaplastic large cell lymphoma, and the approval of ado-trastuzumab emtansine in 2013 for treating HER2-positive metastatic breast cancer, have sparked vigorous research in the field, with >65 ADCs currently in clinical evaluation. This review highlights the ADCs that are approved for marketing, in pivotal clinical trials, or in at least phase II clinical development for treating both hematologic malignancies and solid tumors.
ISSN:0066-4219
1545-326X
DOI:10.1146/annurev-med-061516-121357